Références
- Gougis P, Teixeira L. Oncolytic Viruses: First Validation of a Therapeutic Category that is not so new. Oncologie
(2016) 18:517-522.
- Fountzilas C, Patel S, Mahalingam D. Review: Oncolytic virotherapy, updates and future directions. Oncotarget,
2017, Vol. 8, (No. 60): 102617-102639.
- Wei D, Xu J, Liu X, Chen Z, Bian H. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China. Human Gene
Therapy. 2017.
- Bell J, McFadden G. Viruses for Tumor Therapy. Cell Host & Microbe. 2014;15(3):260-265.
- Krzykawski M. Combined bacterial and viral treatment: a novel anticancer strategy. Central European Journal
of Immunology. 2015; 3:366-372.
- Tortora GJ, Funke BR, Case CL. Microbiology: an introduction ,11th ed. 2013.
- Kierszenbaum A, Tres L. Histology and cell biology. 4th ed. 2016.
- Abd-Elrahman I, Hershko K, Neuman T, Nachmias B, Perlman R, Ben-Yehuda D. The Inhibitor of Apoptosis Protein
Livin (ML-IAP) Plays a Dual Role in Tumorigenicity. Cancer Research. 2009;69(13):5475-5480.
- Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M et al. The Oncolytic Activity of Newcastle Disease
Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the
Inhibitor of Apoptosis Protein Livin. J Virol. 2010; 84(1):639-46.
- Dine J, Gordon R, Shames Y, Kasler M, Barton-Burke M. Immune checkpoint inhibitors: An innovation in immu-
notherapy for the treatment and management of patients with cancer. Asia-Pacific Journal of Oncology Nursing.
2017;4(2):127.
Images:
http://mariafresa.net/data_gallery/photo-cold-cough-flu-in-babies-babycenter-images-CbgX8a-clipart.jpg.
Image de l’arrière plan par : Harryarts / Freepik
Starline / Freepik
ReMed Magazine - Numéro 4
17